郭轶先;常晓丽;惠吴函;方芳;王国祥;邹冬梅;苏力;孙婉玲

• 1:首都医科大学宣武医院血液科，北京 100053

摘要(Abstract)：

关键词(KeyWords)： 急性髓细胞白血病;骨髓增生异常综合征;去甲基化药物;BCL-2 抑制剂

Abstract:

Keywords:

基金项目(Foundation): 北京市自然科学基金(Z200022)

作者(Authors): 郭轶先;常晓丽;惠吴函;方芳;王国祥;邹冬梅;苏力;孙婉玲

DOI: 10.13267/j.cnki.syzlzz.2022.028

参考文献(References)：

• [1] Stone RM. The difficult problem of acute myeloid leukemia in the older adult[J]. CA Cancer J Clin, 2002, 52(6):363-371.
  [2] Shah A, Andersson TM, Rachet B, et al. Survival and cure of acute myeloid leukaemia in England, 1971-2006:a population-based study[J]. Br J Haematol, 2013, 162(4):509-516.
  [3] Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia:report of 82 patients enrolled in an Italian Compassionate Program[J]. Cancer-Am Cancer Soc, 2012, 118(4):1014-1022.
  [4] Issa JP, Garcia-Manero G, Huang X, et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia[J]. Cancer-Am Cancer Soc, 2015, 121(4):556-561.
  [5] Dinardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia[J]. Blood, 2019, 133(1):7-17.
  [6] Dinardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia:a non-randomised, open-label, phase 1b study[J]. Lancet Oncol, 2018, 19(2):216-228.
  [7] Dinardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia:a single-centre, phase 2 trial[J]. Lancet Haematol, 2020, 7(10):e724-736.
  [8] Wei AH, Strickland SJ, Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia:Results from a phase Ⅰb/Ⅱ study[J]. J Clin Oncol, 2019, 37(15):1277-1284.
  [9] Löwenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+years with acute myeloid leukemia:a randomized phase Ⅲ study of the European Organization for Research and Treatment of Cancer Leukemia Group[J]. J Clin Oncol, 1989, 7(9):1268-1274.
  [10] Quintás-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia[J]. Blood, 2012, 120(24):4840-4845.
  [11] Fenaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes:azacitidine compared with low dose ara-C[J]. Br J Haematol, 2010, 149(2):244-249.
  [12] Cashen AF, Schiller GJ, O'donnell MR, et al. Multicenter, phase Ⅱ study of decitabine for the first-line treatment of older patients with acute myeloid leukemia[J]. J Clin Oncol, 2010, 28(4):556-561.
  [13] Montalban-Bravo G, Garcia-Manero G, Jabbour E. Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes[J]. Curr Opin Hematol, 2018, 25(2):146-153.
  [14] Gil-Perez A, Montalban-Bravo G. Management of myelodysplastic syndromes after failure of response to hypomethylating agents[J]. Ther Adv Hematol, 2019, 9(10):153138835.
  [15] 冶秀鹏,包慎,郭莹,等.真性红细胞增多症急性髓细胞白血病转化三例[J].实用肿瘤杂志, 2019, 34(2):172-174.
  [16] Jilg S, Hauch RT, Kauschinger J, et al. Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose[J]. Exp Hematol Oncol, 2019, 16(8):9.
  [17] Ram R, Amit O, Zuckerman T, et al. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study[J]. Ann Hematol, 2019, 98(8):1927-1932.
  [18] Ball BJ, Famulare CA, Stein EM, et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure[J]. Blood Adv, 2020, 4(13):2866-2870.
  [19] Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia[J]. Cancer Discov, 2020, 10(4):536-551.
  [20] Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia[J]. Nat Med, 2015, 21(2):178-184.
  [21] Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase Ⅱ study of venetoclax monotherapy in patients with acute myelogenous leukemia[J]. Cancer Discov, 2016, 6(10):1106-1117.
  [22] Dinardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies[J]. Am J Hematol, 2018, 93(3):401-407.
  [23] Morsia E, Mccullough K, Joshi M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia:Mayo Clinic series on 86 patients[J]. Am J Hematol, 2020, 95(12):1511-1521.
  [24] Wang YW, Tsai CH, Lin CC, et al. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax[J]. Ann Hematol, 2020, 99(3):501-511.
  [25] Abbott D, Cherry E, Amaya M, et al. The propriety of upgrading responses to venetoclax+azacitidine in newly diagnosed patients with acute myeloid leukemia[J]. Leuk Lymphoma, 2020, 62(6):1466-1473.
  [26] Mcmahon CM, Perl AE. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia[J]. Expert Rev Clin Pharmacol, 2019, 12(9):841-849.
  [27] Kadia TM, Reville PK, Borthakur G, et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome:a cohort from a single-centre, single-arm, phase 2 trial[J]. Lancet Haematol, 2021, 8(8):e552-561.
  [28] Bewersdorf JP, Stahl M, Zeidan AM. One plus one does not always equal two, especially with regard to hypomethylating agents:the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant[J]. Expert Rev Hematol, 2019, 12(8):575-578.
  [29] Moujalled DM, Pomilio G, Ghiurau C, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia[J]. Leukemia, 2019, 33(4):905-917.